| Washington Saturday, September 12, 2015, 17:00 Hrs [IST] |
| Vanda Pharmaceuticals Inc. (Vanda), a biopharmaceutical company, announced that a favourable Markman ruling has been issued by the United States District Court for the District of Delaware in the patent infringement lawsuit filed by the company against Roxane Laboratories Inc. (Roxane) regarding Roxane’s submission of an Abbreviated New Drug Application to make and sell a generic version of Fanapt, schizophrenia drug.A Markman ruling, also known as a Claim Construction Ruling, is a court ruling in which the judge determines the meaning of key terms from certain disputed patent claims. The Delaware court, which was asked to construe disputed patent claim terms in US patent number 8,586,610 (‘610), rejected Roxane’s proposed construction of all the disputed claim terms. The ‘610 patent is expected to expire in November 2027.Fanapt is an atypical antipsychotic agent indicated for treatment of schizophrenia in adults. In choosing among treatments, prescribers should consider the ability of Fanapt to prolong the QT interval and the use of other drugs first. Prescribers should also consider the need to titrate Fanapt slowly to avoid orthostatic hypotension, which may lead to delayed effectiveness compared to some other drugs that do not require similar titration. |
Related Articles
-
Here’s a lucrative idea: Turn a drug into an orphan med, reap 6 months extra exclusivity – Courtesy (Fierce Pharma)
Would-be makers of rare disease meds, rejoice: A 6-month exclusivity extension, proposed last year in Congress, has returned. The 21st...
-
Merck scores victory in India patent battle over top diabetes meds! – Courtesy (Fierce Pharma)
In a potentially promising sign for Western drugmakers, Merck ($MRK) scored a victory in its patent battle with India’s Glenmark...
-
Judge Finds Biosimilar Patent Procedures Optional – Courtesy (Pharma Patent)
POSTED BY COURTENAY C. BRINCKERHOFF ON 23 MARCH 2015POSTED IN BIOSIMILARSJudge Seeborg of the U.S. District Court for the Northern District of...
-
Novo Nordisk rejects Baxter patent claim over Novoeight
COPENHAGEN, May 20 (Reuters) – Novo Nordisk said on Wednesday it rejected claims by U.S. rival Baxter International that...
-
Court Cites Objects Of Invention In Claim Construction – Courtesy (Pharma Patents)
POSTED BY COURTENAY C. BRINCKERHOFF ON 24 FEBRUARY 2015POSTED IN CLAIM CONSTRUCTION;FEDERAL CIRCUIT DECISIONSPacing Technologies, LLC v. Garmin International, Inc. is one of...
-
Louisiana Challenge’s AstraZeneca on Antitrust Claims for Asserting Invalid Drug Patents – Courtesy(PATENTLYO)
In March 2015, the state of Louisiana filed suit against AstraZeneca alleging antitrust violations based upon the company’s actions of...
-
The Trans-Pacific Partnership And The Costs of Drug Patent Monopolies – Courtesy(OurFuture.org)
The debate over the Trans-Pacific Partnership (TPP) has taken center stage in policy circles in recent weeks. Its proponents...
-
The Importance of Contracts for Joint Infringement in Patent Cases – Courtesy (IP Litigation Current)
POSTED BY JUSTIN M. SOBAJE ON 19 MAY 2015POSTED IN DIVIDED INFRINGEMENT;DIVIDED INFRINGEMENT;PATENTS;PLEADINGS;SUPREME COURTIt has been about a year since the Supreme...
